Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProCervix in HPV16/18-infected women with normal cytology
NL-OMON35990Active, not recruiting
- Sponsor
- Genticel
- Start
- Jan 2012
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of GTL001 and imiquimod in human papillomavirus infection (5 cohorts), sponsored by Genticel. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Clinical laboratory test changes and 7 more. Started Jan 2012; status: active, not recruiting.
02
Drugs
GTL001imiquimod
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON35990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35990.